Abeona Reports $71.2M Net Income and First ZEVASKYN Patient Treatment
Abeona Therapeutics finished 2025 with $5.8 million in revenue and $71.2 million net income, driven by a $155 million PRV sale, and closed the year with $191.4 million in cash and equivalents. The first commercial ZEVASKYN patient was treated in December and three Qualified Treatment Centers are now operational to support 2026 scale-up.
1. Full Year 2025 Financial Results
Abeona reported $5.8 million in total revenue for 2025, including $3.4 million in license and other revenues and $2.4 million in net product revenue. Net income was $71.2 million, or $1.34 per basic share, reflecting a $155 million gross PRV sale, while cash and equivalents totaled $191.4 million as of December 31.
2. ZEVASKYN Commercial Launch Progress
Following FDA approval in April 2025, Abeona completed its first commercial ZEVASKYN treatment in December 2025 and resumed manufacturing in late January 2026. Multiple patient biopsies have been collected and one treatment has been administered so far in 2026, establishing initial commercial workflows and validating the release assay optimization.
3. QTC Network Expansion and Outlook
The University of Texas Medical Branch in Galveston became Abeona’s fourth Qualified Treatment Center in December, expanding access across Texas and the Gulf Coast. This network growth is expected to streamline patient referrals and accelerate demand as treatment experience builds and the RDEB community shares positive outcomes.